Background: Acquired bilateral nevus of Ota-like macules (ABNOM) is a dermal pigmented lesion common in individuals of Oriental origin. The Q-switched Nd:YAG laser (QSNYL) has been used successfully to treat a variety of benign, dermal, pigmented lesions, including nevus of Ota lesions. The similarity between ABNOM and nevus of Ota suggested that QSNYL may also be effective in the former. Objective: To determine the efficacy and side-effect profiles of QSNYL treatment of ABNOM in Korean patients. Methods: Of 42 Korean patients with ABNOM, 29 were treated with QSNYL (1,064 nm, 3 mm spot size, fluence 8∼ 9.5 J/cm 2 ), for up to 10 sessions each. Clinical photographs were taken before and after treatment. Lesion clearance was graded and complications such as hyperpigmentation, scarring, hypopigmentation, and erythema were assessed. Results: Of the 29 treated patients, 19 (66%) showed excellent or good results. Of the patients who were treated more than 3 times, 76% showed good to excellent results. Two patients experienced post-laser hyperpigmentation (PLH), which persisted for more than one month, but no patient experienced persistent erythema or hypertrophic scarring. Conclusion: QSNYL is safe and effective in the treatment of ABNOM in Korean patients. Short-interval repetitive treatment is especially useful in improving therapeutic results and reducing PLH. 
INTRODUCTION
Acquired bilateral nevus of Ota-like macules (ABNOM), a circumscribed dermal melanocytosis of the face, is fairly common in non-Caucasians, including Koreans and Japanese. ABNOM appears as small, bilateral, blue-brown and/or slate-gray patches on the forehead, temples, eyelids, malar areas, and alae and roots of the nose 1 . In the literature, several modalities of treatment, including cryotherapy 2 and dermabrasion 3 have been tried for ABNOM.
Based on the principles of selective photothermolysis, nevus of Ota has been successfully treated with Q-switched ruby lasers 4, 5 , Q-switched alexandrite lasers 6 , and Q-switched Nd:YAG lasers (QSNYL) 7 . The histological similarities between ABNOM and nevus of Ota suggested that laser therapy may also be successful in the treatment of ABNOM. We therefore assessed the efficacy and side-effect profiles of QSNYL in the treatment of Korean patients with ABNOM.
MATERIALS AND METHODS

Subjects
Our study cohort consisted of 42 individuals (40 women, 2 men) with a clinical diagnosis of ABNOM. None of these patients had received any previous treatments for their lesions. Mean patient age at the first visit was 33.4 years (range, 22 to 52 years). Color of lesions was classified into 3 categories: brown, slate-gray, and blue. All 42 patients had lesions on the zygomatic area, which appeared as mottled brownish-to-bluish macules. Lesions were also observed on the temporal area (12/42, 28%), forehead (4/42, 10%), upper eyelids (3/42, 7%) and nose (2/42, 5%) ( Table 1) . 
QSNYL treatments
A total of 29 of the 42 patients were treated with a QSNYL, at a wavelength of 1064 nm, a pulse duration of 5∼7 nsec, a spot size of 3 mm, and a fluence of 8∼9.5 J/cm 2 .
For all patients we applied topical anesthesia (a eutectic mixture of 2.5% lidocaine HCl and 2.5% prilocaine, EMLA). The therapeutic endpoint was defined as immediate whitening following laser irradiation. Energy densities were reduced if tissue bleeding was prominent. Patients were treated up to 10 times, at intervals ranging from 4 to 12 weeks depending on the degree of post-laser hyperpigmentation (PLH). After each laser session, all patients applied topical mupirocin ointment and sunblocking agents.
Depigmentary cream, such as 4% hydroquinone creams, was applied when PLH occurred. The patients were instructed to keep away from the sun.
Assessment of responses and complications
Responses to laser treatment were clinically assessed by two independent dermatologists using clinical photographs taken at each follow-up visit. Photographs were obtained from the front and side of both cheeks at every visit. The same photographer took these with the same digital camera (D70, Nikon, Japan) and ambient lighting. Responses to treatment were assessed according to the percentage pigment clearing and were classified as excellent (lightening of 75∼100%), good (lightening of 50∼74%), moderate (lightening of 25∼49%), fair (lightening of 10∼ 24%), and poor (lightening of less than 9%). If there was a discrepancy between two observers, the degree of improvement was graded according to the lower score. We evaluated the effects of number of treatment, color of lesions and site of lesions on therapeutic outcomes. Any side effects such as scarring, hyperpigmentation, hypopigmentation and erythema were also assessed at each visit.
Statistical analysis
Spearman correlation analyses were performed to determine the significance of number of treatment, color of lesions and site of lesions. The correlation between the color of lesions and PLH was determined using the Chi- square test for trends. Inter-observer agreement was analyzed by the Kappa statistics. All analyses were performed using SPSS, version 14.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as p＜0.05.
RESULTS
Of the 16 patients younger than 30 years, 8 showed brown-colored lesions and 2 revealed blue-colored macules. In contrast, 5 of 9 patients older than 40 years had blue-colored lesions (Fig. 1) . According to Spearman's correlation analysis, lesions tended to become progressively bluer with age (correlation coefficient, r=0.339, p=0.028).
The Kappa statistic revealed a significant agreement between the two assessments (Kappa=0.904, p＜0.001).
The data collected are summarized in Table 2 . Of the 29 treated patients, 19 (66%) showed excellent or good results (Table 3 , Fig. 2, 3) ; 76% who were treated more than three times had good or excellent result ( (Fig. 4) . However, a significant correlation between color and transient PLH was not demonstrated (p=0.869 by Chisquare test for trend). PLH persisted for more than one month in two patients who presented with brown-colored macules (Fig. 5 ). There were no cases of persistent erythema, hypertrophic scarring, or persistent textural changes.
DISCUSSION
ABNOM, a pigmentary disorder first described in 1984 1 , usually begins as discrete brown macules; these become confluent, slate-gray macules over time 8 . The malar region of the cheek is the most commonly affected area. It is important to clinically and histologically differentiate ABNOM from nevus of Ota, female facial melanosis, and melasma. ABNOM is an acquired disease, usually appearing during the fourth or fifth decades of life, and is usually bilateral. In contrast, nevus of Ota usually develops during the first year of life or during adolescence, is usually unilateral and involves the conjunctival, oral or nasal mucosae, as well as the tympanic membrane. Although dermabrasion has been successful in the treatment of ABNOM 3 , this procedure is highly invasive and is associated with many complications, including scarring, infection and post-inflammatory hyperpigmentation. Therefore, QS lasers are the main treatment modalities for ABNOM as well as for nevus of Ota. In a previous report, of patients undergoing 2∼7 QSNYL treatment sessions at intervals of 2 to 6 months, 30∼100% showed a greater than 50% lightening response and the incidence of PLH ranged from 50∼100%, with differences in clinical responses due to differences in laser parameters and treatments intervals [9] [10] [11] . In our study, 66% of treated patients and 76% of patients who were treated more than three times showed greater than 50% of clearing and only 40% had transient PLH. We found a statistically significant correlation between the number of treatments and therapeutic outcome. This means that clinicians need to consider repeated treatments for resolving ABNOM. We found no color or site-dependent differences in therapeutic outcomes. In contrast to several previous protocols, our repetitive treatment sessions were performed at 1-to 3-month intervals. This short interval time was chosen to improve the rate of clearing and prevent epithelial repigmentation. Epidermal melanin and melanocytes are competing chromophores for dermal pigment laser therapy and increase the risk of post-inflammatory hyperpigmentation. By performing treatment sessions at short intervals, more photons can target the dermal chromophores through the hypopigmented epithelium while avoiding scattering of the beam 12 . In addition, heat has little effect on the hypopigmented epidermis, thereby preventing PLH 13 .
Histologically, in ABNOM dermal melanocytes are scattered throughout the upper and middle portions of the dermis, whereas, in nevus of Ota melanocytes are diffused throughout the entire dermis 1 . In addition, ABNOM is characterized by prominent epidermal hypermelanosis together with dermal melanophages. Variations in color (brown, gray, blue) are due to the proportion of pigmented cells in the epidermis and dermis 14 . Although the pathogenesis of ABNOM is unclear, it may be due to "epidermal melanocyte migration" 1 . This mechanism is consistent with the fact that the color of the macules varies with the maturity of the ABNOM. Initially, these macules are usually brown and discrete, becoming bluish-gray and diffuse over time. The early-stage brown lesions are thought to be due to the presence of melanocytes at the basal layer of the epidermis; their subsequent migration into the dermis leads to a darker bluish-gray color 8, 14 . Although we found no color-dependent differences in the development of transient PLH, two patients with brown macules experienced PLH that persisted for more than 1 month. In agreement with the epidermal migration hypothesis, early-stage brown lesions have more epidermal melanosis, and PLH is more likely to occur in epidermis that contains abundant melanin. Moreover, melanocytes in ABNOM contain immature melanosomes, which are at stage II melanization 2 . In cases of early-stage brown ABNOM, there are more melanocytes with immature melanosomes, and laser treatment may fail to destroy these amelanotic melanocytes; this may activate immature melanocytes, leading to PLH 15 .
Thus, care should be taken when treating patients with early-stage disease. Epidermal melanin in these lesions can be destroyed using an adjuvant modality such as a 532 nm QSNYL, a CO2 laser or bleaching agents 14, 16, 17 .
In conclusion, we have shown here that QSNYL 1064 nm is effective in the treatment of ABNOM. Repeated treatments separated by short time intervals can improve therapeutic results and reduce PLH. In addition, earlystage brown macules are more likely to produce PLH.
